癌症免疫疗法：PD-1受体抑制的阴暗面。
Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
作者信息
Ludin Aya, Zon Leonard I
机构信息
the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts 02138, USA.
the Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, and at the Howard Hughes Medical Institute, Boston.
出版信息
Nature. 2017 Dec 7;552(7683):41-42. doi: 10.1038/nature24759. Epub 2017 Nov 15.
Abstract
Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves.
摘要
抑制蛋白质PD-1可以激活引发针对肿瘤细胞免疫反应的T细胞。但结果表明，在小鼠中，这种免疫疗法会加剧一种涉及T细胞自身的癌症。
相似文献
1
Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
Nature. 2017 Dec 7;552(7683):41-42. doi: 10.1038/nature24759. Epub 2017 Nov 15.
2
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Int J Mol Sci. 2016 Jul 18;17(7):1151. doi: 10.3390/ijms17071151.
3
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Clin Cancer Res. 2013 Oct 1;19(19):5542. doi: 10.1158/1078-0432.CCR-13-2234. Epub 2013 Sep 18.
4
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.
Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18.
5
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9.
6
PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18.
7
Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Biochemistry. 2018 Feb 13;57(6):901-903. doi: 10.1021/acs.biochem.7b01249. Epub 2018 Jan 19.
8
A decade of immune-checkpoint inhibitors in cancer therapy.
Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.
9
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.
10
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
Br J Cancer. 2015 Apr 28;112(9):1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9.
引用本文的文献
1
Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review.
ILIVER. 2022 Nov 4;1(4):225-234. doi: 10.1016/j.iliver.2022.10.001. eCollection 2022 Dec.
2
Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review.
Front Oncol. 2025 Jun 12;15:1494007. doi: 10.3389/fonc.2025.1494007. eCollection 2025.
3
Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells.
Sci Rep. 2025 Apr 7;15(1):11894. doi: 10.1038/s41598-025-92209-z.
4
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.
Probiotics Antimicrob Proteins. 2025 Feb 15. doi: 10.1007/s12602-025-10468-8.
5
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.
Mol Cancer. 2023 May 16;22(1):84. doi: 10.1186/s12943-023-01768-0.
6
Recent advances in sonodynamic immunotherapy.
J Cancer Res Clin Oncol. 2023 Apr;149(4):1645-1656. doi: 10.1007/s00432-022-04190-z. Epub 2022 Jul 13.
7
Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
Front Immunol. 2022 Jun 23;13:938439. doi: 10.3389/fimmu.2022.938439. eCollection 2022.
8
Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis.
J Nanobiotechnology. 2022 Feb 15;20(1):80. doi: 10.1186/s12951-022-01287-y.
9
Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation.
Theranostics. 2021 Jul 25;11(17):8587-8604. doi: 10.7150/thno.62572. eCollection 2021.
10
Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.
Int J Nanomedicine. 2021 Mar 5;16:1889-1899. doi: 10.2147/IJN.S290796. eCollection 2021.
本文引用的文献
1
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Nature. 2017 Dec 7;552(7683):121-125. doi: 10.1038/nature24649. Epub 2017 Nov 15.
2
The diverse functions of the PD1 inhibitory pathway.
Nat Rev Immunol. 2018 Mar;18(3):153-167. doi: 10.1038/nri.2017.108. Epub 2017 Nov 13.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10.
5
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.
6
The emerging role of immune checkpoint inhibition in malignant lymphoma.
Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24.
7
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
8
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
9
Serine-threonine kinases in TCR signaling.
Nat Immunol. 2014 Sep;15(9):808-14. doi: 10.1038/ni.2941.
Zotero 插件